JP7372252B2 - タキサンのナノ粒子を用いる子宮頸部上皮内腫瘍（ｃｉｎ）および子宮頸癌の処置のための局所療法 - Google Patents

タキサンのナノ粒子を用いる子宮頸部上皮内腫瘍（ｃｉｎ）および子宮頸癌の処置のための局所療法 Download PDF

Info

Publication number
JP7372252B2
JP7372252B2 JP2020549671A JP2020549671A JP7372252B2 JP 7372252 B2 JP7372252 B2 JP 7372252B2 JP 2020549671 A JP2020549671 A JP 2020549671A JP 2020549671 A JP2020549671 A JP 2020549671A JP 7372252 B2 JP7372252 B2 JP 7372252B2
Authority
JP
Japan
Prior art keywords
nanoparticles
micron
composition
hydrophobic
taxane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020549671A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021518362A (ja
JP2021518362A5 (https=
JPWO2019178024A5 (https=
Inventor
ギア ディゼレガ
Original Assignee
ディーエフビー ソリア リミテッド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ディーエフビー ソリア リミテッド ライアビリティ カンパニー filed Critical ディーエフビー ソリア リミテッド ライアビリティ カンパニー
Publication of JP2021518362A publication Critical patent/JP2021518362A/ja
Publication of JP2021518362A5 publication Critical patent/JP2021518362A5/ja
Publication of JPWO2019178024A5 publication Critical patent/JPWO2019178024A5/ja
Application granted granted Critical
Publication of JP7372252B2 publication Critical patent/JP7372252B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2020549671A 2018-03-16 2019-03-12 タキサンのナノ粒子を用いる子宮頸部上皮内腫瘍（ｃｉｎ）および子宮頸癌の処置のための局所療法 Active JP7372252B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862643861P 2018-03-16 2018-03-16
US62/643,861 2018-03-16
PCT/US2019/021751 WO2019178024A1 (en) 2018-03-16 2019-03-12 Topical therapy for the treatment of cervical intraepithelial neoplasia (cin) and cervical cancer using nanoparticles of taxanes

Publications (4)

Publication Number Publication Date
JP2021518362A JP2021518362A (ja) 2021-08-02
JP2021518362A5 JP2021518362A5 (https=) 2022-03-10
JPWO2019178024A5 JPWO2019178024A5 (https=) 2022-03-10
JP7372252B2 true JP7372252B2 (ja) 2023-10-31

Family

ID=67906931

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020549671A Active JP7372252B2 (ja) 2018-03-16 2019-03-12 タキサンのナノ粒子を用いる子宮頸部上皮内腫瘍（ｃｉｎ）および子宮頸癌の処置のための局所療法

Country Status (7)

Country Link
US (2) US11497726B2 (https=)
EP (1) EP3765035A4 (https=)
JP (1) JP7372252B2 (https=)
KR (1) KR20200132963A (https=)
CN (1) CN112165949A (https=)
CA (1) CA3092500A1 (https=)
WO (1) WO2019178024A1 (https=)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005507874A (ja) 2001-08-29 2005-03-24 ユーエムディー， インコーポレイテッド 癌治療のための化学療法剤及び膜流出システム阻害剤の経膣送達
US20130211384A1 (en) 2010-07-28 2013-08-15 Fondazione Irccs Istituto Nazionale Dei Tumori Therapeutic agent, composition including said agent, implantable device and process for the treatment of cervical cancer and/or for the prevention of the formation of neoplasms in correspondence of the cervix in a human female genital system
JP2014510756A (ja) 2011-04-01 2014-05-01 フロリダ大学 リサーチファウンデーション インコーポレイティッド 治療薬を局所送達するための感熱性を有する粘膜付着性または皮膚粘着性の浸透促進剤

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
EP1155689B1 (en) 1993-07-19 2006-09-20 Angiotech Pharmaceuticals, Inc. Anti-angiogenic stents and methods of their preparation
US5874029A (en) 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
KR20000015944A (ko) 1996-05-24 2000-03-15 팜 윌리암 엔. 신체 통로의 질병을 치료 또는 예방하기 위한조성물 및 방법
US5756537A (en) 1996-11-08 1998-05-26 Parkash S. Gill, M.D., Inc. Regime for paclitaxel in Kaposi's sarcoma patients
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
BRPI9810945B8 (pt) 1997-06-27 2021-05-25 Abraxis Bioscience Inc formulações de agentes farmacológicos, métodos para sua preparação e métodos para uso das mesmas
US6117949A (en) 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6004573A (en) 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
IL131217A0 (en) 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US6113795A (en) 1998-11-17 2000-09-05 The University Of Kansas Process and apparatus for size selective separation of micro- and nano-particles
IN191203B (https=) 1999-02-17 2003-10-04 Amarnath Prof Maitra
US6365191B1 (en) 1999-02-17 2002-04-02 Dabur Research Foundation Formulations of paclitaxel, its derivatives or its analogs entrapped into nanoparticles of polymeric micelles, process for preparing same and the use thereof
US6406722B1 (en) 1999-02-18 2002-06-18 Robert G. Gallaher Method of treating viral infections and lesions with taxane compounds
US7217735B1 (en) 1999-04-09 2007-05-15 Au Jessie L-S Methods and compositions for enhancing delivery of therapeutic agents to tissues
US6610317B2 (en) 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
CA2371836C (en) 1999-05-27 2006-01-31 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6892091B1 (en) 2000-02-18 2005-05-10 Biosense, Inc. Catheter, method and apparatus for generating an electrical map of a chamber of the heart
CA2410632A1 (en) 2000-06-22 2001-12-27 David S. Garvey Nitrosated and nitrosylated taxanes, compositions and methods of use
US8178123B2 (en) 2001-08-29 2012-05-15 Femina Pharma Incorporated Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
WO2003032906A2 (en) 2001-10-15 2003-04-24 Crititech, Inc. Delivery of poorly soluble drugs
EP1490030B2 (en) 2002-03-20 2010-07-14 Elan Pharma International Limited Nanoparticulate compositions of angiogenesis inhibitors
US20080220075A1 (en) 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
KR100533458B1 (ko) 2002-07-20 2005-12-07 대화제약 주식회사 파클리탁셀의 가용화용 조성물 및 그의 제조 방법
EP1569620A4 (en) 2002-10-30 2006-03-22 Spherics Inc NANOPARTICULAR BIOACTIVE AGENTS
CN103405405A (zh) 2002-12-09 2013-11-27 阿布拉西斯生物科学有限责任公司 组合物和传递药剂的方法
ZA200507752B (en) 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
FR2856301B1 (fr) 2003-06-23 2007-08-03 Galderma Res & Dev Composition sous forme de spray comprenant un actif pharmaceutique, au moins un silicone volatile et une phase non polaire non volatile
US9149440B2 (en) 2003-09-02 2015-10-06 University Of South Florida Nanoparticles for drug-delivery
PL2286794T3 (pl) 2003-10-15 2016-10-31 Zastosowanie kationowych liposomów zawierających paklitaksel
JP4787165B2 (ja) 2003-11-05 2011-10-05 エラン ファーマ インターナショナル，リミティド 表面安定剤としてペプチドを有するナノ粒子組成物
FR2862540B1 (fr) 2003-11-21 2007-03-30 Galderma Res & Dev Composition sous forme de spray comprenant un actif pharmaceutique, au moins un silicone volatile et une phase non polaire non volatile
FR2871695B1 (fr) 2004-06-17 2008-07-04 Galderma Sa Composition pharmaceutique comprenant un agent silicone et deux principes actifs solubilises
FR2871697B1 (fr) 2004-06-17 2007-06-29 Galderma Sa Composition sous forme de spray comprenant une association d'actifs pharmaceutiques, une phase alcoolique, au moins un silicone volatile et une phase huileuse non volatile
US7361683B2 (en) 2004-11-24 2008-04-22 Yung Shin Pharm. Ind., Co., Ltd Paclitaxel aqueous injection solution and methods for preparing the same
US8062658B2 (en) 2004-12-14 2011-11-22 Poly-Med, Inc. Multicomponent bioactive intravaginal ring
MX2007010394A (es) 2005-02-24 2008-02-19 Elan Pharma Int Ltd Formulaciones nanoparticuladas de docetaxel y analogos del mismo.
GB0506139D0 (en) 2005-03-24 2005-05-04 Transphase Ltd A transdermal topical composition and its uses
DE602006021408D1 (de) 2005-04-27 2011-06-01 Univ Leiden Medical Ct Behandlung von hpv-induzierter intraepithelialer anogenitaler neoplasien
WO2006133271A2 (en) 2005-06-06 2006-12-14 The General Hospital Corporation Compositions and methods relating to target-specific photodynamic therapy
AU2006284657B2 (en) 2005-08-31 2012-07-19 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
JP2009519971A (ja) 2005-12-14 2009-05-21 オルガノジェネシス インク． スキンケア組成物及び治療法
US8906392B2 (en) 2005-12-16 2014-12-09 University Of Kansas Nanocluster compositions and methods
US8343962B2 (en) 2006-03-06 2013-01-01 Nuvo Research Inc. Topical formulation
EP2077823B1 (en) 2006-10-11 2012-06-27 Crititech, Inc. Method for precipitation of small medicament particles into use containers
CA2611803C (en) 2006-11-22 2013-03-19 Bj Services Company Well treatment fluid containing viscoelastic surfactant and viscosification activator
EP3470071A1 (en) 2006-12-14 2019-04-17 Abraxis BioScience, LLC Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
TWI405590B (zh) 2007-04-06 2013-08-21 活效製藥股份有限公司 微粉碎化有機化合物粒子之製法
JP5579057B2 (ja) 2007-06-01 2014-08-27 アブラクシス バイオサイエンス， エルエルシー 再発性癌の処置のための方法および組成物
ITMI20071267A1 (it) 2007-06-22 2008-12-23 Fidia Farmaceutici Uso di coniugati dell'acido ialuronico nel trattamento locale di malattie cutanee iperproliferative
HU227970B1 (en) 2007-07-10 2012-07-30 Egis Gyogyszergyar Nyrt Pharmaceutical compositions containing silicones of high volatility
CN101129338A (zh) 2007-08-27 2008-02-27 四川大学 超临界流体新技术微细化抗癌药物紫杉醇
US8486924B2 (en) 2007-11-28 2013-07-16 Celator Pharmaceuticals, Inc. Taxane delivery system
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US8865194B1 (en) 2007-12-20 2014-10-21 Theraplex Company, LLC Reducing tackiness and greasiness of petrolatum-like materials
US20090175810A1 (en) 2008-01-03 2009-07-09 Gareth Winckle Compositions and methods for treating diseases of the nail
US8952075B2 (en) 2008-05-22 2015-02-10 Poly-Med, Inc. Bioactive polymeric liquid formulations of absorbable, segmented aliphatic polyurethane compositions
CN101283976A (zh) * 2008-05-30 2008-10-15 济南基福医药科技有限公司 一种含紫杉烷类药物的抗癌缓释凝胶注射剂
WO2009153774A2 (en) 2008-06-17 2009-12-23 Rosetta Genomics Ltd. Compositions and methods for prognosis of ovarian cancer
MX379265B (es) 2008-06-26 2025-03-11 Anterios Inc Aplicacion dérmica de toxina botulínica en nanoemulsiones para usarse en el tratamiento de trastornos de la piel.
WO2011022652A1 (en) 2009-08-21 2011-02-24 Novan, Inc. Topical gels
US10029013B2 (en) 2009-10-02 2018-07-24 Foamix Pharmaceuticals Ltd. Surfactant-free, water-free formable composition and breakable foams and their uses
GB2474930B (en) 2009-10-02 2012-07-04 Foamix Ltd Topical tetracycline compositions
KR101721865B1 (ko) 2009-10-13 2017-04-03 렉산 파마슈티컬스, 인코포레이티드 항암제의 전달을 위한 폴리머 시스템
CN101829061A (zh) 2010-05-14 2010-09-15 无锡纳生生物科技有限公司 一种紫杉醇纳米颗粒组合物及其制备方法
CN101843582B (zh) 2010-05-18 2011-12-21 南京工业大学 紫杉醇纳米混悬剂及其制备方法
WO2011151418A2 (en) 2010-06-02 2011-12-08 Abbott Gmbh & Co. Kg Nanosusupension formulation comprising a polydimethylsiloxane hydrophobic phase
US8039494B1 (en) 2010-07-08 2011-10-18 Dow Pharmaceutical Sciences, Inc. Compositions and methods for treating diseases of the nail
WO2012017349A2 (en) 2010-08-02 2012-02-09 Ranbaxy Laboratories Limited An improved topical pharmaceutical composition comprising nanonized silver sulfadiazine
US8563535B2 (en) 2011-03-29 2013-10-22 Kamal Mehta Combination composition comprising benzoyl peroxide and adapalene
WO2012130314A1 (en) 2011-03-31 2012-10-04 Elara Pharmaceuticals Gmbh Composition comprising docetaxel
US20140073615A1 (en) 2011-05-02 2014-03-13 Lipidor Ab Treatment of Psoriasis
BR112013033466A8 (pt) 2011-06-27 2018-03-06 Cristal Delivery B V uso de um sistema de liberação controlada e sistema de liberação controlada
HRP20181187T1 (hr) * 2012-04-04 2018-09-21 Halozyme, Inc. Kombinirana terapija s hijaluronidazom i taksanom koji ciljano djeluje na tumor
US9018246B2 (en) 2012-09-05 2015-04-28 Lp Pharmaceutical (Xiamen) Co., Ltd. Transmucosal administration of taxanes
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
JP2014114249A (ja) 2012-12-11 2014-06-26 Kanae Technos:Kk 基剤、及び皮膚外用剤
AU2014224445C1 (en) * 2013-03-04 2017-07-27 Astrazeneca Ab Combination treatment
US8778181B1 (en) 2013-03-14 2014-07-15 Crititech, Inc. Equipment assembly for and method of processing particles
US20140294967A1 (en) 2013-03-28 2014-10-02 Bbs Nanotechnology Llc. Stable nanocomposition comprising paclitaxel, process for the preparation thereof, its use and pharmaceutical compositions containing it
KR20160024985A (ko) 2013-06-28 2016-03-07 바인드 쎄라퓨틱스, 인크. 암 치료를 위한 도세탁셀 중합체성 나노입자
TWI601542B (zh) 2014-04-18 2017-10-11 林信湧 一種用於治療肺癌之吸入式醫藥組成物及其備製方法
WO2015187194A1 (en) 2014-06-01 2015-12-10 Crititech, Inc. Use of paclitaxel particles
WO2016071365A1 (en) 2014-11-03 2016-05-12 Spherium Biomed, S.L. Topical pharmaceutical compositions of paclitaxel
CN105280869B (zh) 2015-01-07 2018-07-31 保定钰鑫电气科技有限公司 一种组合式蓄电池端子连接片
EP3302423B1 (en) 2015-06-04 2022-05-25 Crititech, Inc. Particle production system and particle collection device
CA2998483C (en) 2015-09-16 2022-09-06 Dfb Soria, Llc Delivery of drug nanoparticles and methods of use thereof
BR112018069628A2 (pt) 2016-04-04 2019-02-12 Crititech, Inc. métodos para tratamento de tumor sólido
WO2018170196A1 (en) * 2017-03-15 2018-09-20 Dfb Soria, Llc Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005507874A (ja) 2001-08-29 2005-03-24 ユーエムディー， インコーポレイテッド 癌治療のための化学療法剤及び膜流出システム阻害剤の経膣送達
US20130211384A1 (en) 2010-07-28 2013-08-15 Fondazione Irccs Istituto Nazionale Dei Tumori Therapeutic agent, composition including said agent, implantable device and process for the treatment of cervical cancer and/or for the prevention of the formation of neoplasms in correspondence of the cervix in a human female genital system
JP2014510756A (ja) 2011-04-01 2014-05-01 フロリダ大学 リサーチファウンデーション インコーポレイティッド 治療薬を局所送達するための感熱性を有する粘膜付着性または皮膚粘着性の浸透促進剤

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Adv. Healthcare Mater.，2014年，3，pp.1044-1052
Drug Deliv. and Transl. Res.，2017年，7，pp.817-828
NANO REVIEWS & EXPERIMENTS，2017年，8，1335567

Also Published As

Publication number Publication date
WO2019178024A1 (en) 2019-09-19
CN112165949A (zh) 2021-01-01
EP3765035A4 (en) 2021-10-27
EP3765035A1 (en) 2021-01-20
JP2021518362A (ja) 2021-08-02
US20200405682A1 (en) 2020-12-31
KR20200132963A (ko) 2020-11-25
US11497726B2 (en) 2022-11-15
CA3092500A1 (en) 2019-09-19
US20230038716A1 (en) 2023-02-09

Similar Documents

Publication Publication Date Title
US11633349B2 (en) Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes
JP7152549B2 (ja) 薬物ナノ粒子の送達およびその使用法
JP2018531231A6 (ja) 薬物ナノ粒子の送達およびその使用法
WO2018170210A1 (en) Topical therapy for the treatment of vulvar intraepithelial neoplasia (vin) and genital warts using nanoparticles of taxanes
US20190216767A1 (en) Topical therapy for the treatment of skin keratoses using nanoparticles of taxanes
JP7372252B2 (ja) タキサンのナノ粒子を用いる子宮頸部上皮内腫瘍（ｃｉｎ）および子宮頸癌の処置のための局所療法
HK40120875A (zh) 包含紫杉烷类纳米颗粒的组合物及其用途
HK40015816A (en) Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes
HK40015816B (en) Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220302

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220302

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230407

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230705

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230920

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231019

R150 Certificate of patent or registration of utility model

Ref document number: 7372252

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150